Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Immunovia AB

Ratings ESG MSCI

Ratings ESG MSCI - Immunovia AB

Ratings Immunovia AB: Strengths and Weaknesses

Highlights: Immunovia AB
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses: Immunovia AB
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Rating Financials

Immunovia AB SectorUnited Kingdom

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

More ratings
Fundamental Rankings - Immunovia AB

Rating Valuation

Immunovia AB SectorUnited Kingdom

Global Valuation

-

Enterprise Value

-

EV/Revenue

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings
Fundamental Rankings - Immunovia AB

Rating Consensus

Immunovia AB SectorUnited Kingdom

Consensus

-

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

-

Analysts' recommendations evolution (4 months)

-

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings
Fundamental Rankings - Immunovia AB

Rating Business Predictability

Immunovia AB SectorUnited Kingdom

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

-

Surprise rates

Fundamental Rankings - Immunovia AB

Rating Revisions

Immunovia AB SectorUnited Kingdom

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings
Fundamental Rankings - Immunovia AB


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
4.76M - - - - - -
250B
BBB
156B
A
144B
BBB
61.45B
BBB
50.28B
AAA
46.73B
BBB
48.29B
AAA
45.89B
AAA
43.24B
AAA
Average 84.52B
AA
Weighted average by Cap.
AA